semaglutide and cardiovascular disease FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity Semaglutide and cardiovascular outcomes in

A 2026 report on Direct Meds' GLP-1 platform and LegitScript certification status provides additional context on the company's regulatory standing during a period of heightened industry scrutiny

These distinctions are important when interpreting individual experiences

Will peanut butter sabotage my weight loss on GLP-1 therapy

People sometimes describe that before taking semaglutide, they were constantly thinking about food, but once that noise was quieted, they found it easier to make the [lifestyle] changes they always wanted, says Gudzune

Chest 134(6), 2008

To view or add a comment, sign in Novartis has entered into an exclusive global #licensing and #collaboration #agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for #Alzheimers disease, in a deal valued at up to USD 1.7 billion